Abstract
Purpose. The purpose of this study was to evaluate clinical and radiographic findings of treatments using a new hemostatic agent (Ankaferd blood stopper (ABS)), as compared to ferric sulfate (FS), when used as a pulpotomy medicament in primary teeth. Materials and Methods. The primary molars (70) were selected from 35 children aged 4 to 6 years. The teeth were randomized into two groups for pulpotomy with the ABS (n = 35) and the FS (n = 35) agents. The patients were recalled for clinical and radiographic evaluation at 3-, 6-, 9-, and 12-month intervals. Results. At the 3- and 6-month clinical and radiographic evaluations, total success rates of 100% were observed in each group. In ABS and FS groups, the clinical success rates, however, reduced to 90.9% and 93.9% at the 9-month examination and 84,8% and 90.9% at the 12-month examination, respectively. Similarly, the teeth in the ABS and FS groups had radiographic success rates of 90.9% and 93.9% at 9 months and 84.8% and 87.8% at 12 moths, respectively. Conclusion. Although the findings indicated that ABS agents may be useful agents for pulpotomy medicament, further long-term and comprehensive histological investigations of ABS treatments are necessary.
Highlights
In primary dentition, pulpotomy is a common therapeutic procedure for the management of asymptomatic teeth with exposure caries [1]
The findings indicated that ABS agents may be useful agents for pulpotomy medicament, further long-term and comprehensive histological investigations of ABS treatments are necessary
Several factors affect the success of pulpotomy, and the hemostatic capability of the pulpotomy agent is one of the most important factors in improving the favorable prognosis of vital pulp therapy [6]
Summary
Pulpotomy is a common therapeutic procedure for the management of asymptomatic teeth with exposure caries [1]. An FC solution at a 1 : 5 ratio is the gold standard in the pulpotomy of primary teeth because it is relatively simple to use, it is economical, and it has a high rate of clinical success [1, 2]. Several factors affect the success of pulpotomy, and the hemostatic capability of the pulpotomy agent is one of the most important factors in improving the favorable prognosis of vital pulp therapy [6]. Ferric sulfate (FS) has been commonly used as a pulpotomy agent to control pulpal bleeding in vital pulp therapy for 30 years. FS induces hemostasis and the formation of a sealing membrane at the interrupted vessel of pulp tissue by agglutinating the blood proteins with ferric and sulfate ions [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
